Are you sure?

Richter and Forest Laboratories announce positive trial results of drug for bipolar mania

Hungarian drug company Richter Gedeon and US partner Forest Laboratories said on Wednesday that the preliminary results of Phase III trials of a new antipsychotic agent Cariprazine (RGH-188) for the treatment of bipolar mania have been positive.

In terms of the Young Mania Rating Scale (YMRS), a primary end-point for the testing, patients suffering from acute mania treated with Cariprazine showed significant improvement in symptoms compared to placebo-treated patients beginning already on the fourth day of treatment, the drug companies said.

Analysis of data will be completed over the coming weeks.

Clinical trials of Cariprazine for the treatment of schizophrenia and bipolar depression are ongoing, and use of the agent in the supplementary treatment of major depressive-disorder is also being examined.